

WHAT IS CLAIMED IS:

- But Cl
1. *Lactobacillus* sp. BC-Y009 (KCTC-0774BP).
  2. *Acetobacter* sp. BC-Y058 (KCTC-0773BP).

sub B2


3. A pharmaceutical composition comprising at least one microorganism selected from the group consisting of *Acetobacter* sp., *Leuconostoc* sp., *Bacillus* sp., *Lactobacillus* sp., *Streptococcus* sp., *Bifidobacterium* sp., *Lactococcus* sp. and *Pediococcus* sp. bacteria in an amount effective to prevent or treat obesity and a pharmaceutically acceptable carrier, wherein the microorganism is capable of producing polysaccharide.

4. The pharmaceutical composition according to claim 3, wherein said microorganism is selected from the group consisting of *Acetobacter* sp., *Lactobacillus* sp. and *Lactococcus* sp. bacteria.

5. The pharmaceutical composition according to claim 3, wherein said microorganism is selected from the group consisting of *Acetobacter xylinum*, *Acetobacter* BC-Y058, *Acetobacter hansénii*, *Acetobacter pasteurianus*, *Acetobacter aceti*, *Leuconostoc* sp., *Bacillus* sp., *Lactobacillus* BC-Y009, *Lactobacillus brevis*, *Lactobacillus helveticus*, *Lactobacillus bulgaricus*, *Lactobacillus casei*, *Lactobacillus kefir*, *Lactobacillus keriranofaciens*, *Lactobacillus bifidus*, *Lactobacillus sake*, *Lactobacillus reuteri*, *Lactobacillus lactis*, *Lactobacillus delbrueckii*, *Lactobacillus helveticusglucos* var. *jugurti*., *Lactococcus cremoris*, *Bifidobacterium bifidum*, *Streptococcus thermophilus* and *Pediococcus* sp.

09655836 051604

fred



---

100

Rest a2

at  
t  
,  
co  
on  
C  
tic  
s  
s

Dr.

OK  
further  
limits  
to specific  
species of  
the group

*Lactobacillus reuteri*, *Lactobacillus lactis*, *Lactobacillus delbrueckii*,  
*Lactobacillus helveticus* glucos var. *jugurti*., *Lactococcus cremoris*,  
*Bifidobacterium bifidum*, *Streptococcus thermophilus* and *Pediococcus*  
*sp.*

13. The pharmaceutical composition according to claim 10,  
wherein said microorganism is selected from the group consisting of  
*Acetobacter* BC-Y058 and *Lactobacillus* BC-Y009. *free*

14. The pharmaceutical composition according to claim 10,  
which is a formulation suitable for oral administration. *reg.*

15. The pharmaceutical composition according to claim 10,  
which is a formulation coated with enteric coating materials.

16. A method for *preventing or* treating obesity, comprising  
administering to a subject in need thereof a pharmaceutical composition  
comprising at least one microorganism selected from the group consisting  
of *Acetobacter sp.*, *Leuconostoc sp.*, *Bacillus sp.*, *Lactobacillus sp.*,  
*Streptococcus sp.*, *Bifidobacterium sp.*, *Lactococcus sp.* and *Pediococcus*  
*sp.* bacteria in an amount effective to prevent or treat obesity and a  
pharmaceutically acceptable carrier, wherein the microorganism is capable  
of producing polysaccharide.

17. The method according to claim 16, wherein the  
pharmaceutical composition comprises at least one microorganism  
selected from the group consisting of *Acetobacter sp.*, *Lactobacillus sp.*  
and *Lactococcus sp.* bacteria.

18. The method according to claim 16, wherein the  
pharmaceutical composition comprises at least one microorganism  
selected from the group consisting of *Acetobacter xylinum*, *Acetobacter*

BC-Y058, *Acetobacter hansenii*, *Acetobacter pasteurianus*, *Acetobacter aceti*, *Leuconostoc sp.*, *Bacillus sp.*, *Lactobacillus* BC-Y009, *Lactobacillus brevis*, *Lactobacillus helveticus*, *Lactobacillus bulgaricus*, *Lactobacillus casei*, *Lactobacillus kefir*, *Lactobacillus keriranofaciens*, *Lactobacillus bifidus*, *Lactobacillus sake*, *Lactobacillus reuteri*, *Lactobacillus lactis*, *Lactobacillus delbrueckii*, *Lactobacillus helveticusglucos var. jugurti.*, *Lactococcus cremoris*, *Bifidobacterium bifidum*, *Streptococcus thermophilus* and *Pediococcus sp.*

19. The method according to claim 16, wherein the pharmaceutical composition comprises at least one microorganism selected from the group consisting of *Acetobacter* BC-Y058 and *Lactobacillus* BC-Y009.

20. The method according to claim 16, wherein the pharmaceutical composition is a formulation suitable for oral administration.

21. The method according to claim 16, wherein the pharmaceutical composition is a formulation coated with enteric coating materials.

22. The method according to claim 20, wherein the pharmaceutical composition is a formulation coated with enteric coating materials.

23. A method for preventing or treating diabetes mellitus, comprising administering to a subject in need thereof a pharmaceutical composition comprising at least one microorganism selected from the group consisting of *Acetobacter sp.*, *Leuconostoc sp.*, *Bacillus sp.*, *Lactobacillus sp.*, *Streptococcus sp.*, *Bifidobacterium sp.*, *Lactococcus sp.* and *Pediococcus sp.* bacteria in an amount effective to prevent or treat

09855836 051601

2003

201-23  
diabetes mellitus and a pharmaceutically acceptable carrier, wherein the microorganism is capable of producing polysaccharide.

24. The method according to claim 23, wherein the pharmaceutical composition comprises at least one microorganism selected from the group consisting of *Acetobacter sp.*, *Lactobacillus sp.* and *Lactococcus sp.* bacteria.

25. The method according to claim 23, wherein the pharmaceutical composition comprises at least one microorganism selected from the group consisting of *Acetobacter xylinum*, *Acetobacter* BC-Y058, *Acetobacter hansenii*, *Acetobacter pasteurianus*, *Acetobacter aceti*, *Leuconostoc sp.*, *Bacillus sp.*, *Lactobacillus* BC-Y009, *Lactobacillus brevis*, *Lactobacillus helveticus*, *Lactobacillus bulgaricus*, *Lactobacillus casei*, *Lactobacillus kefir*, *Lactobacillus keriranofaciens*, *Lactobacillus bifidus*, *Lactobacillus sake*, *Lactobacillus reuteri*, *Lactobacillus lactis*, *Lactobacillus delbrueckii*, *Lactobacillus helveticusglucos var. jugurti.*, *Lactococcus cremoris*, *Bifidobacterium bifidum*, *Streptococcus thermophilus* and *Pediococcus sp.*

26. The method according to claim 23, wherein the pharmaceutical composition comprises at least one microorganism selected from the group consisting of *Acetobacter* BC-Y058 and *Lactobacillus* BC-Y009.

27. The method according to claim 23, wherein the pharmaceutical composition is a formulation suitable for oral administration.

28. The method according to claim 23, wherein the pharmaceutical composition is a formulation coated with enteric coating materials.

09855836 051601

29. A method for controlling or preventing weight gain, comprising administering to a subject in need thereof a pharmaceutical composition comprising at least one microorganism selected from the group consisting of *Acetobacter sp.*, *Leuconostoc sp.*, *Bacillus sp.*, *Lactobacillus sp.*, *Streptococcus sp.*, *Bifidobacterium sp.*, *Lactococcus sp.* and *Pediococcus sp.* bacteria in an effective amount and a pharmaceutically acceptable carrier, wherein the microorganism is capable of producing polysaccharide.

30. The method according to claim 29, wherein the said microorganism is selected from the group consisting of *Acetobacter* BC-Y058 and *Lactobacillus* BC-Y009.

31. The method according to claim 29, wherein the pharmaceutical composition is suitable for oral administration.

32. The method according to claim 29, wherein the pharmaceutical composition is coated with enteric coating materials.

33. A method for reducing weight gain, comprising administering to a subject in need thereof a pharmaceutical composition comprising at least one microorganism selected from the group consisting of *Acetobacter sp.*, *Leuconostoc sp.*, *Bacillus sp.*, *Lactobacillus sp.*, *Streptococcus sp.*, *Bifidobacterium sp.*, *Lactococcus sp.* and *Pediococcus sp.* bacteria in an effective amount and a pharmaceutically acceptable carrier, wherein the microorganism is capable of producing polysaccharide.

34. The method according to claim 33, wherein the said microorganism is selected from the group consisting of *Acetobacter* BC-Y058 and *Lactobacillus* BC-Y009.

09855836-051601

35. The method according to claim 33, wherein the pharmaceutical composition is suitable for oral administration.

36. The method according to claim 33, wherein the pharmaceutical composition is coated with enteric coating materials.

37. A method for controlling blood glucose level, comprising administering to a subject in need thereof a pharmaceutical composition comprising at least one microorganism selected from the group consisting of *Acetobacter sp.*, *Leuconostoc sp.*, *Bacillus sp.*, *Lactobacillus sp.*, *Streptococcus sp.*, *Bifidobacterium sp.*, *Lactococcus sp.* and *Pediococcus sp.* bacteria in an effective amount and a pharmaceutically acceptable carrier, wherein the microorganism is capable of producing polysaccharide.

38. The method according to claim 37, wherein the said microorganism is selected from the group consisting of *Acetobacter* BC-Y058 and *Lactobacillus* BC-Y009.

39. The method according to claim 37, wherein the pharmaceutical composition is suitable for oral administration.

40. The method according to claim 37, wherein the pharmaceutical composition is coated with enteric coating materials.

41. The method according to claim 37, wherein a normal blood glucose level is not affected.

42. A method for controlling absorption of blood lipid, comprising administering to a subject in need thereof a pharmaceutical composition comprising at least one microorganism selected from the group consisting of *Acetobacter sp.*, *Leuconostoc sp.*, *Bacillus sp.*, *Lactobacillus sp.*, *Streptococcus sp.*, *Bifidobacterium sp.*, *Lactococcus sp.*

09855836 054504  
T09T50" 9C855836

and *Pediococcus* sp. bacteria in an effective amount and a pharmaceutically acceptable carrier, wherein the microorganism is capable of producing polysaccharide.

43. The method according to claim 42, wherein the said microorganism is selected from the group consisting of *Acetobacter* BC-Y058 and *Lactobacillus* BC-Y009.

44. The method according to claim 42, wherein the pharmaceutical composition is suitable for oral administration.

45. The method according to claim 42, wherein the pharmaceutical composition is coated with enteric coating materials.

add  
B4